Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Shionogi Eyes FY2024 Japan Filing of Regeneration-Inducing Medicine
Shionogi is aiming to file redasemtide, a “regeneration-inducing medicine” licensed from Osaka University spinout StemRIM, for Japanese regulatory approval for the treatment of dystrophic epidermolysis bullosa in FY2024. The drug maker revealed the plan at an R&D event on October…
To read the full story
Related Article
- Redasemtide Delivers Mixed PII Results in Stroke, DEB
September 10, 2026
- Shionogi Begins Global PIIb Stroke Study for Regeneration-Inducing Medicine
April 11, 2023
- Redasemtide Yields Positive PII Data in Stroke: Shionogi/StemRIM
December 14, 2021
- PII Study Now underway for StemRIM’s Redasemtide for Chronic Liver Disease
March 18, 2021
- Hirosaki University to Test StemRIM’s Redasemtide for Knee Osteoarthritis
December 2, 2020
- StemRIM Bags 1.7 Billion Yen from Shionogi for Expanded Deal on Regeneration-Inducing Medicine
July 28, 2020
- Shionogi, StemRIM Extend Collaboration for “Regeneration-Inducing Medicine”
July 1, 2020
BUSINESS
- Asahi Kasei Rebrands Pharma Units under Common Global Name
September 30, 2026
- Chugai Licenses RAF-MEK Molecular Glue to InxMed
September 30, 2026
- OB-GYN Chief Hopes for April 2027 NIP Addition of RSV Antibodies
September 30, 2026
- KM Biologics Eyes Plasma Product Capacity Expansion with Govt Backing
September 30, 2026
- Japan Needs to Boost COVID Vaccine Uptake, Expert Says
September 30, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…